LivaNova (LIVN) Q4 FY25 earnings call

LivaNova concluded FY25 with robust double-digit revenue growth and significant operating margin expansion, driven by strong execution in its core cardiopulmonary and epilepsy businesses. The company is strategically investing in innovation, particularly in obstructive sleep apnea (OSA) and a digital health platform, while benefiting from improved VNS therapy reimbursement. Management is focused on leveraging its core for sustained growth and expanding into high-growth markets.